

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,
Petitioner,

v.

CIPLA LTD.,
Patent Owner.

Case IPR2017-00807
Patent 8,168,620 B2

Before JAMES T. MOORE, ZHENYU YANG, and
KRISTI L. R. SAWERT, *Administrative Patent Judges*.

SAWERT, *Administrative Patent Judge*.

Conduct of the Proceeding
37 C.F.R. § 42.5

On April 24, 2018, the Supreme Court held that a final written decision under 35 U.S.C. § 318(a) must decide the patentability of all claims challenged in the petition. *SAS Inst., Inc. v. Iancu*, --- S. Ct. ----, 2018 WL 1914661, at *10 (U.S. Apr. 24, 2018). In our Decision on Institution, we determined that Petitioner demonstrated a reasonable likelihood that it would establish that at least one of the challenged claims of the '620 patent is unpatentable. Paper 11, 27. Pursuant to the holding in *SAS*, we modify our institution decision to institute on all of the challenged claims and all of the grounds presented in the Petition.

The parties remain free to stipulate to changes in the schedule under the terms of the Scheduling Order. If, after conferring, the parties wish to otherwise change the schedule or submit briefing not set forth in the Scheduling Order, the parties must, within one week of the date of this Order, request a conference call with the panel to seek authorization for such changes or briefing.

In consideration of the foregoing, it is hereby:

ORDERED that, pursuant to 35 U.S.C. § 314(a), we modify our institution decision to include review of all challenged claims and all grounds presented in the Petition;

FURTHER ORDERED that Petitioner and Patent Owner shall confer to determine whether they desire any changes to the schedule or briefing not already permitted under the Scheduling Order, and, if so, request a conference call with the panel to seek authorization for such changes or briefing within one week of the date of this Order.

IPR2017-00807
Patent 8,168,620 B2

FOR PETITIONER:

Michael R. Houston
Joseph P. Meara
James P. McParland
FOLEY & LARDNER LLP
mhouston@foley.com
jmeara-pgp@foley.com
jmcparland@foley.com

Tyler C. Liu
ARGENTUM PHARMACEUTICALS LLC
tliu@agpharm.com

FOR PATENT OWNER:

Dennies Varughese
Deborah A. Sterling
Adam C. LaRock
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
dvarughe-PTAB@skgf.com
dsterlin-PTAB@skgf.com
alarock-PTAB@skgf.com